Losartan angiotensin-receptor blockers

Losartan Monopotassium Salt - Losartan Potassium - DuP753 - DuP 753 - DuP-753 - MK954 - MK 954 - MK-954 - Cozaar - Losartan

Acute myocardial infarction

All type of patients:  1 trials  - OPTIMAAL

Losartan vs Captopril

No demonstrated result

suggested Cough by 75% (not demonstrated)

suggested angiodema by 72% (not demonstrated)

suggested Adverse events by 48% (not demonstrated)

Atrial fibrillation

Patients without history of AF (primary prevention):  1 trials  - LIFE (AF ancillary study)

losartan vs atenolol

No demonstrated result

suggested atrial fibrillation by 34% (not demonstrated)

Diabetes type 2

All type of patients:  1 trials  - RENAAL

losartan vs placebo

No demonstrated result

suggested microvascular events by 21% (not demonstrated)

See more clinical conditions

Patients with hypertension:  1 trials  - LIFE (diabetic subgroup)

losartan vs atenolol

No demonstrated result

suggested cardiovascular events by 24% (not demonstrated)

suggested Cardiovascular death by 35% (not demonstrated)

suggested All cause death by 39% (not demonstrated)

Patients with or without hypertension:  2 trials  - RENAAL - LIFE (diabetic subgroup)

losartan vs atenolol

No demonstrated result

suggested cardiovascular events by 24% (not demonstrated)

suggested Cardiovascular death by 35% (not demonstrated)

suggested All cause death by 39% (not demonstrated)

losartan vs placebo

No demonstrated result

suggested microvascular events by 21% (not demonstrated)

Diabetic kidney disease

All type of patients:  1 trials  - RENAAL

losartan vs placebo

No demonstrated result

suggested microvascular events by 21% (not demonstrated)

Heart failure

All type of patients:  11 trials  - Dickstein et al. - ELITE - ELITE II - Hamroff et al. - Lang et al. - Losartan Phase III International - Losartan Phase III U.S. - Losartan phase II S - losartan phase II US - HEAAL - NCT00090259

losartan vs captopril

No demonstrated result

suggested Cough by 96% (not demonstrated)

suggested Adverse events by 41% (not demonstrated)

losartan vs enalapril

No demonstrated result

losartan vs losartan

No demonstrated result

losartan vs placebo

No demonstrated result

suggested All cause death by 72% (not demonstrated)

losartan 150mg vs losartan 50mg

No demonstrated result

suggested Death from any cause or hospitalization for any reason by 10% (not demonstrated)

suggested hospitalisation for heart failure by 13% (not demonstrated)

losartan+ACE inhibitor vs ACE inhibitor only

No demonstrated result

See more clinical conditions

Patients already receiving ACE inhibitor:  3 trials  - Dickstein et al. - Hamroff et al. - Lang et al.

losartan vs enalapril

No demonstrated result

losartan+ACE inhibitor vs ACE inhibitor only

No demonstrated result

Patients previously untreated with ACE inhibitors:  2 trials  - ELITE - ELITE II

losartan vs captopril

No demonstrated result

suggested Cough by 96% (not demonstrated)

suggested Adverse events by 41% (not demonstrated)

Hypertension

All diseases requiring ACEi (HF, CHD, HT,...):  5 trials  - RENAAL - LIFE - ELITE - ELITE-II - OPTIMAAL

losartan vs atenolol

No demonstrated result

lung cancer by 141% (harmful effect)

suggested cardiovascular events by 14% (not demonstrated)

suggested stroke (fatal and non fatal) by 25% (not demonstrated)

suggested Diabetes onset by 25% (not demonstrated)

Losartan vs Captopril

No demonstrated result

losartan vs placebo

No demonstrated result

suggested Heart failure by 29% (not demonstrated)

See more clinical conditions

All type of patient:  2 trials  - RENAAL - LIFE

losartan vs atenolol

No demonstrated result

lung cancer by 141% (harmful effect)

suggested cardiovascular events by 14% (not demonstrated)

suggested stroke (fatal and non fatal) by 25% (not demonstrated)

suggested Diabetes onset by 25% (not demonstrated)

losartan vs placebo

No demonstrated result

suggested Heart failure by 29% (not demonstrated)

Diabetic patients :  2 trials  - RENAAL - LIFE (diabetic subgroup)

losartan vs atenolol

No demonstrated result

suggested cardiovascular events by 24% (not demonstrated)

suggested Cardiovascular death by 35% (not demonstrated)

suggested All cause death by 39% (not demonstrated)

losartan vs placebo

No demonstrated result

suggested microvascular events by 21% (not demonstrated)

Patients with additional risk factor:  1 trials  - LIFE

losartan vs atenolol

No demonstrated result

lung cancer by 141% (harmful effect)

suggested cardiovascular events by 14% (not demonstrated)

suggested stroke (fatal and non fatal) by 25% (not demonstrated)

suggested Diabetes onset by 25% (not demonstrated)

Miscellaneous

All type of patients:  2 trials  - RENAAL - LIFE

losartan vs atenolol

No demonstrated result

lung cancer by 141% (harmful effect)

suggested cardiovascular events by 14% (not demonstrated)

suggested stroke (fatal and non fatal) by 25% (not demonstrated)

suggested Diabetes onset by 25% (not demonstrated)

losartan vs placebo

No demonstrated result

suggested Heart failure by 29% (not demonstrated)

Patients at high risk for cardiovascular events

All type of patients:  2 trials  - RENAAL - LIFE

losartan vs atenolol

No demonstrated result

lung cancer by 141% (harmful effect)

suggested cardiovascular events by 14% (not demonstrated)

suggested stroke (fatal and non fatal) by 25% (not demonstrated)

suggested Diabetes onset by 25% (not demonstrated)

losartan vs placebo

No demonstrated result

suggested Heart failure by 29% (not demonstrated)